$YMAB
Y-mAbs Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000155837023005073 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $20.25M $31.45M $65.27M
YoY Change 93.12% 227.64% 87.03%
Cost Of Revenue $2.083M $2.020M $7.467M
YoY Change 13.76% 38.26% 224.09%
Gross Profit $18.17M $29.43M $57.80M
YoY Change 109.91% 261.64% 77.34%
Gross Profit Margin 89.71% 93.58% 88.56%
Selling, General & Admin $12.25M $10.79M $60.94M
YoY Change -8.83% -28.7% 11.67%
% of Gross Profit 67.43% 36.68% 105.43%
Research & Development $13.42M $19.79M $91.57M
YoY Change -41.44% -31.19% -1.79%
% of Gross Profit 73.86% 67.24% 158.43%
Depreciation & Amortization $182.0K $230.0K $839.0K
YoY Change -6.67% -20.96% 7.29%
% of Gross Profit 1.0% 0.78% 1.45%
Operating Expenses $25.67M $30.58M $152.5M
YoY Change -29.38% -30.33% 3.18%
Operating Profit -$7.501M -$1.153M -$94.81M
YoY Change -72.92% -96.78% -17.86%
Interest Expense $40.00K
YoY Change -97.89%
% of Operating Profit
Other Income/Expense, Net $1.111M $2.310M -$757.0K
YoY Change -397.86% -303.52% -59.13%
Pretax Income -$6.390M $1.157M -$95.57M
YoY Change -122.77% -103.14% 72.9%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.390M $1.157M -$95.57M
YoY Change -77.23% -103.14% 72.9%
Net Earnings / Revenue -31.55% 3.68% -146.43%
Basic Earnings Per Share -$0.15 -$2.19
Diluted Earnings Per Share -$0.15 $0.03 -$2.19
COMMON SHARES
Basic Shares Outstanding 43.68M 43.67M 43.70M
Diluted Shares Outstanding 43.67M 43.70M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $92.63M $105.8M $105.8M
YoY Change -40.9% -41.75% -41.75%
Cash & Equivalents $92.63M $105.8M $105.8M
Short-Term Investments
Other Short-Term Assets $3.730M $5.452M $5.452M
YoY Change -38.88% -27.04% -27.04%
Inventory $8.945M $6.702M $6.702M
Prepaid Expenses
Receivables $18.70M $12.53M $12.53M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $124.0M $130.4M $130.4M
YoY Change -30.23% -35.51% -35.51%
LONG-TERM ASSETS
Property, Plant & Equipment $511.0K $604.0K $2.343M
YoY Change -69.89% -67.3% -58.82%
Goodwill
YoY Change
Intangibles $2.898M $2.986M
YoY Change 79.11% 79.56%
Long-Term Investments
YoY Change
Other Assets $8.661M $5.680M $5.680M
YoY Change 26.66% 79.18% 79.18%
Total Long-Term Assets $13.44M $11.01M $11.01M
YoY Change 0.98% 4.63% 4.63%
TOTAL ASSETS
Total Short-Term Assets $124.0M $130.4M $130.4M
Total Long-Term Assets $13.44M $11.01M $11.01M
Total Assets $137.4M $141.5M $141.5M
YoY Change -28.06% -33.52% -33.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.843M $14.18M $14.18M
YoY Change -39.68% 4.6% 4.6%
Accrued Expenses $16.22M $13.24M $14.11M
YoY Change 25.46% 5.59% -1.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.92M $28.28M $28.28M
YoY Change -10.75% 1.47% 1.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $817.0K $802.0K $3.951M
YoY Change -2.16% -5.76% -17.72%
Total Long-Term Liabilities $817.0K $802.0K $3.951M
YoY Change -2.16% -5.76% -17.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.92M $28.28M $28.28M
Total Long-Term Liabilities $817.0K $802.0K $3.951M
Total Liabilities $29.62M $32.24M $32.24M
YoY Change -11.79% -1.35% -1.35%
SHAREHOLDERS EQUITY
Retained Earnings -$442.4M -$436.0M
YoY Change 20.05% 28.07%
Common Stock $4.000K $4.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $107.8M $109.2M $109.2M
YoY Change
Total Liabilities & Shareholders Equity $137.4M $141.5M $141.5M
YoY Change -28.06% -33.52% -33.52%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$6.390M $1.157M -$95.57M
YoY Change -77.23% -103.14% 72.9%
Depreciation, Depletion And Amortization $182.0K $230.0K $839.0K
YoY Change -6.67% -20.96% 7.29%
Cash From Operating Activities -$13.12M -$8.661M -$75.92M
YoY Change -47.35% -74.42% -25.97%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 84.00K
YoY Change -100.0% -100.0% -99.92%
NET CHANGE
Cash From Operating Activities -13.12M -8.661M -75.92M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000 84.00K
Net Change In Cash -13.13M -8.661M -75.80M
YoY Change -47.13% -74.69% -213.26%
FREE CASH FLOW
Cash From Operating Activities -$13.12M -$8.661M -$75.92M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$8.661M -$75.92M
YoY Change -74.08% -26.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001722964
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 ymab Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 ymab Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2021Q4 ymab Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 ymab Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
354700
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
354700
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
354700
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
354700
CY2022Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38650
CY2022 dei Entity Registrant Name
EntityRegistrantName
Y-mAbs Therapeutics, Inc.
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4619612
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
230 Park Avenue
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 3350
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10169
CY2022 dei City Area Code
CityAreaCode
646
CY2022 dei Local Phone Number
LocalPhoneNumber
885-8505
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
YMAB
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
551000000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43677767
CY2022 dei Auditor Firm
AuditorFirmId
238
CY2022 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2022 dei Auditor Location
AuditorLocation
Florham Park, New Jersey
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105762000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181564000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12531000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7712000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6702000
CY2021Q4 us-gaap Inventory Net
InventoryNet
5512000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5452000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
7473000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
130447000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
202261000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
604000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1847000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1739000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3842000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2986000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1663000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5680000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3170000
CY2022Q4 us-gaap Assets
Assets
141456000
CY2021Q4 us-gaap Assets
Assets
212783000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14175000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13552000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13241000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12540000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
868000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1783000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28284000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27875000
CY2022Q4 ymab Accrued Milestone Payments Noncurrent
AccruedMilestonePaymentsNoncurrent
2250000
CY2021Q4 ymab Accrued Milestone Payments Noncurrent
AccruedMilestonePaymentsNoncurrent
2100000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
899000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1851000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
802000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
851000
CY2022Q4 us-gaap Liabilities
Liabilities
32235000
CY2021Q4 us-gaap Liabilities
Liabilities
32677000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43670109
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43670109
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43694716
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43694716
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
543929000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
519206000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1331000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1371000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436043000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-340475000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109221000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
180106000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141456000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
212783000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
65267000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34897000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7467000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2304000
CY2022 ymab Royalty Expense Excluding Costs Included In Cost Of Goods And Services Sold
RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold
100000
CY2021 ymab Royalty Expense Excluding Costs Included In Cost Of Goods And Services Sold
RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold
210000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91572000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93245000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60939000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54571000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
160078000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
150330000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-94811000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-115433000
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
62010000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-757000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1852000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-95568000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-55275000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-40000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1897000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-95608000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53378000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43703663
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43703663
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43181808
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43181808
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
105836000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107725000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
589000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
19334000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1897000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-55275000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
180106000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84000
CY2022 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
963000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
25602000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-40000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-95568000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109221000
CY2022 us-gaap Profit Loss
ProfitLoss
-95568000
CY2021 us-gaap Profit Loss
ProfitLoss
-55275000
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
62010000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
839000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
782000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
25602000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
19334000
CY2022 ymab Foreign Currency Transaction Gain Loss Before Tax And Other Transactions
ForeignCurrencyTransactionGainLossBeforeTaxAndOtherTransactions
-3577000
CY2021 ymab Foreign Currency Transaction Gain Loss Before Tax And Other Transactions
ForeignCurrencyTransactionGainLossBeforeTaxAndOtherTransactions
-1897000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4819000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7712000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1190000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5512000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
360000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-256000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2510000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-120000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-919000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4180000
CY2022 ymab Increase Decrease In Accrued Liabilities And Other
IncreaseDecreaseInAccruedLiabilitiesAndOther
-573000
CY2021 ymab Increase Decrease In Accrued Liabilities And Other
IncreaseDecreaseInAccruedLiabilitiesAndOther
1384000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75921000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102556000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
667000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
300000
CY2021 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
62010000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
61043000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107725000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
84000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
589000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
84000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108314000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75802000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
66930000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181564000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114634000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105762000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181564000
CY2022 ymab Intangible Assets Costs Incurred But Not Yet Paid
IntangibleAssetsCostsIncurredButNotYetPaid
1500000
CY2021 ymab Intangible Assets Costs Incurred But Not Yet Paid
IntangibleAssetsCostsIncurredButNotYetPaid
1500000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
347000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1754000
CY2022 ymab Acquisition Of Treasury Shares Upon Repayment Of Secured Promissory Note
AcquisitionOfTreasurySharesUponRepaymentOfSecuredPromissoryNote
963000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1—ORGANIZATION AND DESCRIPTION OF BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:32.4pt;margin:0pt 13.95pt 0pt 3pt;">Y-mAbs Therapeutics, Inc. (“we,” “us,” “our,” the “Company,” or “Y-mAbs”) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company is leveraging its proprietary antibody platforms and deep expertise in the field of antibodies to develop a broad portfolio of innovative medicines and has several ongoing clinical trials in progress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.15pt;margin:0pt;"><span style="font-size:9.15pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is headquartered in New York and was incorporated on April 30, 2015 under the laws of the State of Delaware.</p>
CY2022 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 2—BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except for the quarter ended March 31, 2021, the Company has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development; technological uncertainty; uncertainty regarding patents and proprietary rights; uncertainty in obtaining the FDA approval in the United States and regulatory approval in other jurisdictions; marketing or sales capability or experience; uncertainty in getting adequate payer coverage and reimbursement; dependence on key personnel; compliance with government regulations and the need to obtain additional financing. The Company’s drug candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance reporting capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s drug candidates are in various stages of development. DANYELZA (naxitamab-gqgk) received accelerated approval by the FDA in November 2020, but there can be no assurance that the Company’s other research and development efforts will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development and commercialization efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative cash flows from operations since inception, and had an accumulated deficit of $436,043,000 as of December 31, 2022 and $340,475,000 as of December 31, 2021. Through December 31, 2022, the Company has funded its operations primarily through proceeds from sales of shares of its common stock, including its initial public offering in September 2018 and its subsequent public offerings in November 2019 and February 2021, as well as additional funding from the sales of DANYELZA and from the sale of the DANYELZA PRV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 22, 2021, the Company announced the closing of its public offering of 2,804,878 shares of its common stock, at a public offering price of $41.00 per share, which included the exercise in full of the underwriters’ option to purchase 365,853 additional shares of common stock. The aggregate gross proceeds to the Company, before deducting underwriting discounts and commissions and offering expenses payable by the Company, were approximately $115,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2022, the Company had cash and cash equivalents of $105,762,000, and as of December 31, 2021 the Company had cash and cash equivalents of $181,564,000. As of the issuance date of the financial statements for the year ended December 31, 2022, the Company expects that its cash and cash equivalents at </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">December 31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next twelve months, irrespective of whether any additional product approvals are obtained. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may raise additional capital to fund future operations through the sale of its securities, incurring debt, entering into licensing or collaboration agreements with partners, grants or other sources of financing. These financing sources are in addition to successful commercialization of DANYELZA and our product candidates which we may obtain regulatory approval and marketing authorization. The Company’s commercialization strategy may be either directly or with a collaborator or distributor. Sufficient funds may not be available to the Company on attractive terms or at all when needed from any such financing. If the Company is unable to obtain additional financing from these or other sources when needed, it will likely be necessary to take other actions to enhance the Company’s liquidity position which may include significantly reducing the current rate of spending through delaying or scaling back current operations, or suspending certain research and development programs and other operational programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying consolidated financial statements reflect the accounts of the Company and its wholly-owned subsidiary and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.</p>
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436043000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-340475000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105762000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181564000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, net product revenues, the accrual for research and development expenses, the accrual of milestone and royalty payments, the valuation of stock options, and asset impairments. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The full extent to which the COVID-19 pandemic and macroeconomic conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets.</p>
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91572000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company product sales are made through arrangements primarily with three national specialty distributors in the United States of America. As of December 31, 2022, the receivables balances from such distributors totaled 94% of our outstanding accounts receivable. The Company has contractual payment terms with each of its customers and the Company monitors their financial performance, historical payment terms and credit worthiness to timely assess and respond to any changes in their credit profile. </p>
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
1200000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q4 us-gaap Residual Value Of Leased Asset
ResidualValueOfLeasedAsset
0
CY2022 ymab Payment Terms Discount For Prompt Payment Percent
PaymentTermsDiscountForPromptPaymentPercent
0.02
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93245000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
662000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
645000
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
617000
CY2021 ymab Costs Incurred As Result Of Global Intangible Low Taxed Income
CostsIncurredAsResultOfGlobalIntangibleLowTaxedIncome
0
CY2022 ymab Costs Incurred As Result Of Global Intangible Low Taxed Income
CostsIncurredAsResultOfGlobalIntangibleLowTaxedIncome
0
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
25602000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
19334000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-40000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1897000
CY2021Q4 ymab Reserve For Discounts Balance
ReserveForDiscountsBalance
13000
CY2021Q4 ymab Contractual Allowance And Government Rebate Liability Balance
ContractualAllowanceAndGovernmentRebateLiabilityBalance
3027000
CY2021Q4 ymab Sales Return Liability Balance
SalesReturnLiabilityBalance
61000
CY2021Q4 ymab Reserves And Allowances Balance
ReservesAndAllowancesBalance
3101000
CY2022 ymab Reserve For Discounts Additions
ReserveForDiscountsAdditions
102000
CY2022 ymab Contractual Allowance And Government Rebate Liability Additions
ContractualAllowanceAndGovernmentRebateLiabilityAdditions
5660000
CY2022 ymab Sales Return Liability Additions
SalesReturnLiabilityAdditions
381000
CY2022 ymab Reserves And Allowances Additions
ReservesAndAllowancesAdditions
6143000
CY2022 ymab Reserve For Discounts Reduction
ReserveForDiscountsReduction
82000
CY2022 ymab Contractual Allowance And Government Rebate Liability Reduction
ContractualAllowanceAndGovernmentRebateLiabilityReduction
3996000
CY2022 ymab Sales Return Liability Reduction
SalesReturnLiabilityReduction
398000
CY2022 ymab Reserves And Allowances Reductions
ReservesAndAllowancesReductions
4476000
CY2022 ymab Contractual Allowance And Government Rebate Change In Estimate
ContractualAllowanceAndGovernmentRebateChangeInEstimate
1786000
CY2022 ymab Reserves For Discounts And Allowances Change In Estimate
ReservesForDiscountsAndAllowancesChangeInEstimate
1786000
CY2022Q4 ymab Reserve For Discounts Balance
ReserveForDiscountsBalance
33000
CY2022Q4 ymab Contractual Allowance And Government Rebate Liability Balance
ContractualAllowanceAndGovernmentRebateLiabilityBalance
2905000
CY2022Q4 ymab Sales Return Liability Balance
SalesReturnLiabilityBalance
44000
CY2022Q4 ymab Reserves And Allowances Balance
ReservesAndAllowancesBalance
2982000
CY2022 ymab Contractual Allowance And Government Rebate Change In Estimate
ContractualAllowanceAndGovernmentRebateChangeInEstimate
1786000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-95568000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-95568000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55275000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-55275000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43703663
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43703663
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43181808
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43181808
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7113122
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6716035
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11317000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4741000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
666000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
771000
CY2022Q4 ymab Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11983000
CY2021Q4 ymab Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5512000
CY2022Q4 ymab Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11983000
CY2021Q4 ymab Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5512000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
1200000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2986000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
314000
CY2022 ymab Intangible Assets Costs Incurred But Not Yet Paid
IntangibleAssetsCostsIncurredButNotYetPaid
1500000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1663000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
137000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
354700
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1212500
CY2022Q4 ymab Accrued Licensing Milestone And Royalty Payments Current
AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent
4002000
CY2021Q4 ymab Accrued Licensing Milestone And Royalty Payments Current
AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent
3090000
CY2022Q4 ymab Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
932000
CY2021Q4 ymab Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
915000
CY2022Q4 ymab Accrued Compensation And Board Fees Current
AccruedCompensationAndBoardFeesCurrent
2445000
CY2021Q4 ymab Accrued Compensation And Board Fees Current
AccruedCompensationAndBoardFeesCurrent
1877000
CY2022Q4 ymab Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
2977000
CY2021Q4 ymab Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
2622000
CY2022Q4 ymab Accrued Sales Reserves Current
AccruedSalesReservesCurrent
2474000
CY2021Q4 ymab Accrued Sales Reserves Current
AccruedSalesReservesCurrent
2615000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
411000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1421000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13241000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12540000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
2646000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2608000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2286000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2216000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
997000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
490000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
419000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1906000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
139000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1767000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1953000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1025000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
550000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
445000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3973000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
339000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3634000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M9D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M13D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2021Q4 ymab Total Shares Authorized
TotalSharesAuthorized
105500000
CY2022Q4 ymab Total Shares Authorized
TotalSharesAuthorized
105500000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5500000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022 ymab Number Of Votes Per Common Stock
NumberOfVotesPerCommonStock
1
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43670109
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43694716
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6687128
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.43
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
26412000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M15D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
653000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.53
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
240361
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
28.32
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7079767
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.27
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3112000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4948467
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.47
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3112000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.64
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.03
CY2022Q4 ymab Deferred Compensation Arrangement Cash Bonus Value
DeferredCompensationArrangementCashBonusValue
1091000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-87827000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47275000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-7741000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-8000000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-95568000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55275000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-95568000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55275000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
18000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
304000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
18000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
304000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-18000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-304000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-18000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-304000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20069000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11607000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-5661000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-5523000
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
861000
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-1734000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-95000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-80000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
25116000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20978000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1749000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1904000
CY2022 ymab Effective Income Tax Rate Reconciliation Uncertain Tax Position Amount
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount
18000
CY2021 ymab Effective Income Tax Rate Reconciliation Uncertain Tax Position Amount
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount
304000
CY2022 ymab Effective Income Tax Rate Reconciliation Deferred Adjustments Amount
EffectiveIncomeTaxRateReconciliationDeferredAdjustmentsAmount
969000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
610000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-434000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2657000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4316000
CY2022Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
263000
CY2021Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
38000
CY2022Q4 ymab Deferred Tax Assets Accrued Royalty
DeferredTaxAssetsAccruedRoyalty
914000
CY2021Q4 ymab Deferred Tax Assets Accrued Royalty
DeferredTaxAssetsAccruedRoyalty
377000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13353000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9222000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
86072000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
88968000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
16799000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
15050000
CY2022Q4 ymab Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
413000
CY2021Q4 ymab Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1015000
CY2022Q4 ymab Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
435000
CY2021Q4 ymab Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
960000
CY2022Q4 ymab Deferred Tax Assets Capitalized Research And Experimentation
DeferredTaxAssetsCapitalizedResearchAndExperimentation
21902000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
572000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
479000
CY2022Q4 ymab Deferred Tax Assets Net Of Liabilities Gross
DeferredTaxAssetsNetOfLiabilitiesGross
142554000
CY2021Q4 ymab Deferred Tax Assets Net Of Liabilities Gross
DeferredTaxAssetsNetOfLiabilitiesGross
117437000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
142554000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
117437000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
304000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
18000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
304000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
322000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
304000

Files In Submission

Name View Source Status
0001558370-23-005073-index-headers.html Edgar Link pending
0001558370-23-005073-index.html Edgar Link pending
0001558370-23-005073.txt Edgar Link pending
0001558370-23-005073-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ymab-20221231.xsd Edgar Link pending
ymab-20221231x10k.htm Edgar Link pending
ymab-20221231x10k001.jpg Edgar Link pending
ymab-20221231x10k002.jpg Edgar Link pending
ymab-20221231x10k003.jpg Edgar Link pending
ymab-20221231x10k005.jpg Edgar Link pending
ymab-20221231x10k006.jpg Edgar Link pending
ymab-20221231x10k007.jpg Edgar Link pending
ymab-20221231x10k009.jpg Edgar Link pending
ymab-20221231x10k010.jpg Edgar Link pending
ymab-20221231xex10d41.htm Edgar Link pending
ymab-20221231xex10d42.htm Edgar Link pending
ymab-20221231xex21d1.htm Edgar Link pending
ymab-20221231xex23.htm Edgar Link pending
ymab-20221231xex31d1.htm Edgar Link pending
ymab-20221231xex31d2.htm Edgar Link pending
ymab-20221231xex32d1.htm Edgar Link pending
ymab-20221231xex32d2.htm Edgar Link pending
ymab-20221231xex4d4.htm Edgar Link pending
ymab-20221231_cal.xml Edgar Link unprocessable
ymab-20221231_def.xml Edgar Link unprocessable
ymab-20221231_lab.xml Edgar Link unprocessable
ymab-20221231_pre.xml Edgar Link unprocessable
ymab-20221231x10k_htm.xml Edgar Link completed